Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study

Table 4

Outcomes within 48 hours after cangrelor administration.

All-cause death	26 (2.6%)
BARC 5a	1 (0.1%)
BARC 5b	5 (0.5%)
Cardiac death	18 (1.8%)
Death, other	2 (0.2%)
Non-fatal bleeding more than BARC 2
BARC 3a	11 (1.1%)
BARC 3b	11 (1.1%)
BARC 3c	1 (0.1%)
Acute myocardial infarction	2 (0.2%)
Stent thrombosis	2 (0.2%)
Ischemic stroke	2 (0.2%)

BARC: Bleeding Academic Research Consortium.